1. Home
  2. News

News

infographic of 11 countries in FORCE-initiative

Joining a Europe-wide alliance to scale-up research on rare and hard-to-treat cancers

The Anticancer Fund is now part of FORCE, a major European initiative supporting research on rare and hard-to-treat cancers. Alongside 13 non-profit partners from 11 countries, we’re working to bring better, evidence-based treatments to patients who urgently need them.

Milestone 1000 patients in trials Anticancer Fund

More than 1.000 patients participating in Anticancer Fund clinical trials

On International Clinical Trials Day, we’ve reached a milestone: more than 1.000 patients are participating in our 7 ongoing clinical trials across 31 countries. These numbers represent more than data — they represent progress, and lives. Discover how smart research is driving change.

Brain tumour in children - U-R-Immune Glioma trial by Anticancer Fund

New clinical trial targets aggressive brain tumours in children and young adults

We started a global trial, U-R-Immune Glioma, investigating whether Immune therapy can offer an alternative treatment for children and young adults with brain tumours. In collaboration with SickKids and CHEO in Canada.

ReDO: cimetidine as an anti-cancer agent

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience, 8, 485. doi:10.3332/ecancer.2014.485

Inconsistencies and questionable reliability of Yamamoto's publication on GcMAF

Ugarte, A., Bouche, G., & Meheus, L. (2014). Inconsistencies and questionable reliability of the publication "immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF" by Yamamoto et al. Cancer Immunology Immunotherapy, 63(12), 1347-8. doi: 10.1007/s00262-014-1587-y

Repurposing Drugs in Oncology (ReDO) Project

Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience, 8, 442. doi:10.3332/ecancer.2014.442